文献速递头颈与中枢神经肿瘤

抗表皮生长因子受体单克隆抗体联合顺铂和5-氟尿嘧啶治疗根治性放疗后转移性鼻咽癌患者的多中心开放标签II期临床试验

Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial.
PubMed 文献 · Ann Oncol · 2019-01-01

这项单臂II期试验评估尼妥珠单抗联合顺铂和5-氟尿嘧啶(PF)方案一线治疗根治性放疗后复发转移性鼻咽癌的疗效与不良反应。共入组35例患者,客观缓解率为71.4%,疾病控制率为85.7%,中位无进展生存期7.0个月,中位总生存期16.3个月。主要3/4级不良事件为白细胞减少(62.9%)。

要点

  • 尼妥珠单抗联合PF方案一线治疗复发转移性鼻咽癌的客观缓解率为71.4%(25/35),疾病控制率为85.7%(30/35)。
  • 中位无进展生存期为7.0个月(95%CI 5.8-8.2),中位总生存期为16.3个月(95%CI 11.4-21.3)。
  • 唯一主要3/4级不良事件为白细胞减少,发生率为62.9%。

核心结论

  • 尼妥珠单抗联合PF化疗作为复发转移性鼻咽癌的一线化疗方案显示出潜在疗效且耐受性良好。

研究设计与样本

  • 单臂II期临床试验,采用Simon最优两阶段设计计算样本量,从十家机构招募符合入选标准的患者(ClinicalTrials.gov; NCT01616849),共入组35例(第一阶段13例,第二阶段22例)。
  • 所有患者接受每周尼妥珠单抗200 mg联合顺铂100 mg/m2 D1和5-氟尿嘧啶4 g/m2持续输注D1-4,每3周一次,最多6个周期。
  • 主要终点为客观缓解率,次要终点包括疾病控制率、无进展生存期、总生存期和不良事件。

主要发现

  • 总客观缓解率为71.4%(25/35),疾病控制率为85.7%(30/35)。
  • 中位无进展生存期为7.0个月(95%CI 5.8-8.2),中位总生存期为16.3个月(95%CI 11.4-21.3)。
  • 非计划探索性分析提示,接受尼妥珠单抗≥2400 mg且PF≥4个周期的患者相比未达到者,客观缓解率更优(88.9% vs 12.5%,P < 0.001),中位无进展生存期7.4个月 vs 2.7个月(P = 0.081),中位总生存期17.0个月 vs 8.0个月(P = 0.202)。
  • 有利亚组包括肺转移患者[HROS 0.324(95%CI 0.146-0.717),P = 0.008]和无病间期>12个月的患者[HROS 0.307(95%CI 0.131-0.724),P = 0.004],但转移负荷未见差异。
  • 唯一主要3/4级不良事件为白细胞减少(62.9%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We conducted a single-arm phase II trial to evaluate the efficacy and adverse effects (AEs) of an anti-epidermal growth factor receptor monoclonal antibody, nimotuzumab, combined with cisplatin and 5-fluorouracil (PF) as first-line treatment in recurrent metastatic nasopharyngeal carcinoma after radical radiotherapy. METHODS: Patients who met the eligibility criteria were recruited from ten institutions (ClinicalTrials.gov; NCT01616849). A Simon optimal two-stage design was used to calculate the sample size. All patients received weekly nimotuzumab (200 mg) added to cisplatin (100 mg/m2 D1) and 5-fluorouracil (4 g/m2 continuous infusion D1-4) every 3-weekly for a maximum of six cycles. Primary end point was objective response rate (ORR). Secondary end points included disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and AEs. RESULTS: A total of 35 patients were enrolled (13 in stage 1 and 22 in stage 2). Overall ORR and DCR were 71.4% (25/35) and 85.7% (30/35), respectively. Median PFS and OS were 7.0 (95% CI 5.8-8.2) months and 16.3 (95% CI 11.4-21.3) months, respectively. Unplanned exploratory analyses suggest that patients who received ≥2400 mg nimotuzumab and ≥4 cycles of PF had superior ORR, PFS and OS than those who did not (88.9% versus 12.5%, P < 0.001; 7.4 versus 2.7 months, P = 0.081; 17.0 versus 8.0 months, P = 0.202). Favourable subgroups included patients with lung metastasis [HROS 0.324 (95% CI 0.146-0.717), P = 0.008] and disease-free interval of >12 months [HROS 0.307 (95% CI 0.131-0.724), P = 0.004], but no difference was observed for metastatic burden. The only major grade 3/4 AE was leukopenia (62.9%). CONCLUSION: Combination nimotuzumab-PF chemotherapy demonstrates potential efficacy, and is well tolerated as first-line chemotherapy regimen in recurrent metastatic nasopharyngeal carcinoma.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Zhao C, Miao J, Shen G, et al. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. Ann Oncol. 2019. PMID: 30689735. doi:10.1093/annonc/mdz020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。